Search - tctmd.com

Displaying 1 - 20 of 177

Sort: Relevancy | Date

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Conference News ACC 2025

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Yael L. Maxwell

April 07, 2025

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

L.A. McKeown

March 31, 2025

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Presenter: Luke Laffin

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News Conference News ACC 2024

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

Michael O'Riordan

April 15, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Shelley Wood

April 11, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

Presentation ACC 2024

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Presenter: Martin S. Maron

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

Advertisement

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content